In addition to those products already partnered or licensed, Biota has a number of projects approaching key milestones of commercial interest:
Biota, together with our Japanese based partner, Daiichi Sankyo, have developed
a second generation of inhaled antiviral compounds for influenza, called long-acting inhaled neuraminidase inhibitors (LANI). The lead product, Inavir® (laninamivir), has been approved for sale in Japan and Biota has been awarded a contract from the Office of Biomedical Advanced Research (BARDA) within the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS) for the advanced development of laninamivir. The contract has a value of up to US$231 milllion over a five year period.
Biota's human rhinovirus (HRV) drug for the prevention and treatment of one of the
major causes of the common cold, BTA798, has completed Phase I, Phase IIa and Phase IIb clinical trials. Biota is prepared to accept expressions of interest from partners interested in this program.
Biota's preclinical stage respiratory syncytial virus (RSV) drug for the prevention and treatment of one of the major causes of morbidity in children, the elderly and immunocomprised patients is available for licensing.
Readers who would like to know more about these or other potential opportunities,
should contact Biota's Vice President Business Development, Dr Leigh Farrell
on +61 (3) 9915 3700 or firstname.lastname@example.org.